Matthew Galsky, MD

Articles

Key Takeaways and Closing Thoughts on ADCs

August 29th 2024

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Emerging ADCs in Development

August 22nd 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

ADC Sequencing

August 22nd 2024

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

Management of Emetogenicity of Antibody-Drug Conjugates

August 15th 2024

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

Managing Hematologic AEs Associated with ADC Treatments

August 15th 2024

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

Dr Galsky on the FDA Approval of Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

February 12th 2024

Matthew Galsky, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab in metastatic urothelial carcinoma.

Dr Galsky on the Efficacy of Adjuvant Nivolumab in the CheckMate 274 Trial in mUC

July 20th 2023

Matthew Galsky, MD, discusses how updated findings from the phase 3 CheckMate 274 study confirm the efficacy of adjuvant systemic immunotherapy in metastatic urothelial carcinoma.

Dr Galsky on Atezolizumab Plus Chemotherapy in Metastatic Urothelial Carcinoma

July 10th 2023

Matthew Galsky, MD, discusses final results from the phase 3 IMvigor130 trial in patients with metastatic urothelial cancer.

Dr Galsky on the Importance of Improved Disease Classification Within Non–Clear Cell RCC

May 15th 2023

Matthew Galsky, MD, discusses the importance of developing specific disease classifications within non–clear cell renal cell carcinomas.

Dr Galsky on the Need for Novel Drug Classes and Non–Cross-Resistant Options in mRCC

May 8th 2023

Matthew Galsky, MD, explains how the development of novel drug classes and therapeutic combinations could address unmet needs in patients with metastatic renal cell carcinoma.

Dr. Galsky on the Rationale for the CheckMate-274 Trial in Urothelial Cancer

March 8th 2023

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate-274 trial in patients with urothelial cancer.

Dr. Galsky on Initial Data From the CheckMate 274 Trial in Urothelial Cancer

June 1st 2022

Matthew Galsky, MD, discusses the design and findings of the phase 3 CheckMate 274 trial in urothelial cancer.

Dr. Galsky on the Rationale of the CheckMate 274 Trial in Urothelial Carcinoma

May 24th 2022

Matthew Galsky, MD, discusses the rationale of the phase 3 CheckMate 274 trial in urothelial cancer.

Dr. Galsky on Updated CheckMate 274 Data With Adjuvant Nivolumab in Urothelial Carcinoma

May 15th 2022

Matthew Galsky, MD, discusses long-term data from the phase 3 CheckMate 274 trial evaluating adjuvant nivolumab vs placebo in patients with high-risk, muscle-invasive urothelial cancer.

Dr. Galsky the Evolution of Standard Options in Urothelial Carcinoma

December 23rd 2021

Matthew Galsky, MD, discusses the evolution of standard of care treatment options in urothelial carcinoma.

Dr. Galsky on Developments in SOC Metastatic Urothelial Cancer Treatment

November 22nd 2021

Matthew Galsky, MD, discusses key developments in the standard-of-care treatment of patients with metastatic or advanced urothelial cancer.

New Therapies Set Stage for Dramatic Changes in Bladder Cancer

November 18th 2019

The number of new therapies that have shown singleagent activity in metastatic disease, the earlier use of immune checkpoint blockade, and our continued attempts to refine our knowledge of the pathogenesis of urothelial carcinoma are expected to dramatically change treatment algorithms and outcomes over the next 5 to 10 years.

Dr. Galsky on Maintenance Pembrolizumab in Urothelial Cancer

July 23rd 2019

Matthew Galsky, MD, discusses the HCRN GU14-182 study, which looked at maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer.

Dr. Galsky Discusses Neoadjuvant Immunotherapy in Bladder Cancer

August 22nd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immunotherapy in bladder cancer.

Dr. Galsky on Neoadjuvant Immune Checkpoint Blockade in Bladder Cancer

August 3rd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses neoadjuvant immune checkpoint inhibition in patients with bladder cancer.